References
1. Iacobucci I, and Mullighan CG. Genetic Basis of Acute Lymphoblastic
Leukemia. J Clin Oncol. 2017;35(9):975-83.
2. Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al.
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.J Clin Oncol. 2015;33(27):2938-48.
3. Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, et al.
Outcome of children with multiply relapsed B-cell acute lymphoblastic
leukemia: a therapeutic advances in childhood leukemia & lymphoma
study. Leukemia. 2018;32(11):2316-25.
4. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et
al. Tisagenlecleucel in Children and Young Adults with B-Cell
Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48.
5. Li L, Liu J, Xu M, Yu H, Lv C, Cao F, et al. Treatment response,
survival, safety, and predictive factors to chimeric antigen receptor T
cell therapy in Chinese relapsed or refractory B cell acute lymphoblast
leukemia patients. Cell Death Dis. 2020;11(3):207.
6. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.N Engl J Med. 2018;378(5):449-59.
7. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et
al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic
Toxicity Associated with Immune Effector Cells. Biol Blood Marrow
Transplant. 2019;25(4):625-38.
8. Brudno JN, and Kochenderfer JN. Recent advances in CAR T-cell
toxicity: Mechanisms, manifestations and management. Blood Rev.2019;34:45-55.
9. Gonzalez Castro LN, and Dietrich J. Evaluation and management of
chimeric antigen receptor (CAR) T-cell-associated neurotoxicity.Neurooncol Pract. 2021;8(3):259-65.
10. Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C,
et al. Beyond the storm - subacute toxicities and late effects in
children receiving CAR T cells. Nat Rev Clin Oncol.2021;18(6):363-78.
11. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A,
Bollard CM, et al. Management guidelines for paediatric patients
receiving chimeric antigen receptor T cell therapy. Nat Rev Clin
Oncol. 2019;16(1):45-63.
12. Zou Y, Chen XJ, Liu XM, Guo Y, Yang WY, Chen YM, et al. [Long-Term
Outcome of 940 Children with Newly Diagnosed Acute Lymphoblastic
Leukemia Treated with CCLG-ALL 2008: A Prospective Single Center Study
in China]. Zhongguo Shi Yan Xue Ye Xue Za Zhi.2020;28(4):1075-80.
13. Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser
HA, Schlaak M, et al. Cytokine release syndrome. J Immunother
Cancer. 2018;6(1):56.
14. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL,
et al. Chimeric antigen receptor T-cell therapy - assessment and
management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
15. Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute
A, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release
syndrome without attenuation of antileukemic efficacy. Blood.2019;134(24):2149-58.
16. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S,
et al. Management of Immunotherapy-Related Toxicities, Version 1.2019.J Natl Compr Canc Netw. 2019;17(3):255-89.
17. Liu Y, Chen X, Wang D, Li H, Huang J, Zhang Z, et al. Hemofiltration
Successfully Eliminates Severe Cytokine Release Syndrome Following CD19
CAR-T-Cell Therapy. J Immunother. 2018;41(9):406-10.
18. Xiao X, He X, Li Q, Zhang H, Meng J, Jiang Y, et al. Plasma Exchange
Can Be an Alternative Therapeutic Modality for Severe Cytokine Release
Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.Clin Cancer Res. 2019;25(1):29-34.
19. Heng G, Jia J, Li S, Fu G, Wang M, Qin D, et al. Sustained
Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T
Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin
Cancer Res. 2020;26(7):1606-15.
20. Aygun F, Varol F, Durak C, Talip Petmezci M, Kacar A, Dursun H, et
al. Evaluation of Continuous Renal Replacement Therapy and Therapeutic
Plasma Exchange, in Severe Sepsis or Septic Shock in Critically Ill
Children. Medicina (Kaunas). 2019;55(7).
21. Ning B, Ye S, Lyu Y, Yin F, and Chen Z. Effect of high-volume
hemofiltration on children with sepsis. Transl Pediatr.2020;9(2):101-7.
22. Lin JH, Chen YC, Lu CL, Hsu YN, and Wang WJ. Application of plasma
exchange in association with higher dose CVVH in Cytokine Storm
Complicating COVID-19. J Formos Med Assoc. 2020;119(6):1116-8.
23. Pan J, Deng B, Ling Z, Song W, Xu J, Duan J, et al. Ruxolitinib
mitigates steroid-refractory CRS during CAR T therapy. J Cell Mol
Med. 2021;25(2):1089-99.
24. Hong R, Hu Y, and Huang H. Biomarkers for Chimeric Antigen Receptor
T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for
Personalized Management and Prognostic Prediction. Front Immunol.2021;12:627764.
25. Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, et al.
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid
Recovery. Biol Blood Marrow Transplant. 2020;26(6):1071-6.